Development of a risk score for BNP ≥100 pg/mL enables prediction of elevated natriuretic peptide levels using clinical variables before blood testing.
Key findingDevelopment of a risk score for BNP ≥100 pg/mL enables prediction of elevated natriuretic peptide le
What the researchers found
Development of a risk score for BNP ≥100 pg/mL enables prediction of elevated natriuretic peptide levels using clinical variables before blood testing.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
2,809 participants aged ≥40 years. BNP threshold: ≥100 pg/mL. BNP measured every 2 years.
How the study worked
In publication.
Who was studied
Japanese adults aged ≥40 years from the Suita Study population-based cohort
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study.
BMC cardiovascular disorders, 25(1), 649
Citation
Arafa, Ahmed; Kato, Yuka; Matsumoto, Chisa; Khairan, Paramita; Maeda, Saori; Kokubo, Yoshihiro. (2025). Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study.. BMC cardiovascular disorders, 25(1), 649. https://doi.org/10.1186/s12872-025-05031-w